Latest 2 Cases This Week: Federal Trade Commission v. AbbVie Inc (3d Cir.), Wooster Floral & Gifts, LLC v. Green Thumb Floral & Garden Center, ...

Joe, Joey, Joe-Baby, Sexist: Where’s Your Imposter Syndrome?

JOANNA L. GROSSMAN

SMU Dedman School of Law professor Joanna L. Grossman responds to a recent Wall Street Journal op-ed criticizing soon-to-be First Lady Jill Biden for using the academic title she earned. Professor Grossman dissects the op-ed, penned by a retired lecturer at Northwestern University, and explains the deep and pervasive sexism behind it.

Read More

Federal Trade Commission v. AbbVie Inc

Court: US Court of Appeals for the Third Circuit

Docket: 18-2758

Opinion Date: December 4, 2020

Judge: Hardiman

Areas of Law: Antitrust & Trade Regulation, Drugs & Biotech, Intellectual Property, Patents

AndroGel, a testosterone replacement therapy, generated billions of dollars in sales, The Federal Trade Commission sued the owners of an AndroGel patent under Section 13(b) of the Federal Trade Commission Act, 21 U.S.C. 301, alleging that they filed sham patent infringement suits against Teva and Perrigo and entered into an anticompetitive reverse-payment agreement with Teva. The FTC accused the defendants of trying to monopolize and restrain trade over AndroGel. The District Court dismissed the FTC’s claims to the extent they relied on a reverse-payment theory but found the defendants liable for monopolization on the sham-litigation theory. The court ordered the defendants to disgorge $448 million in profits but denied the FTC’s request for an injunction. The Third Circuit reversed in part. The district court erred by rejecting the reverse-payment theory and in concluding that the defendants’ litigation against Teva was a sham. The court did not err in concluding the Perrigo litigation was a sham and that the defendants had monopoly power in the relevant market. The FTC has not shown that monopolization entitles it to any remedy. The court did not abuse its discretion in denying injunctive relief. The court erred by ordering disgorgement because that remedy is unavailable under Section 13(b).

Wooster Floral & Gifts, LLC v. Green Thumb Floral & Garden Center, Inc.

Court: Supreme Court of Ohio

Citation: 2020-Ohio-5614

Opinion Date: December 15, 2020

Judge: DeWine

Areas of Law: Antitrust & Trade Regulation, Trademark

The Supreme Court affirmed the decision of the court of appeals affirming the trial court's judgment concluding that Green Thumb did not violate Ohio's Deceptive Trade Practices Act, holding that Wooster Floral & Gifts, LLC failed to demonstrate that Green Thumb Floral & Garden Center, Inc.'s use of the domain name www.woosterfloral.com caused a likelihood of confusion as to the source of goods sold on the website. Green Thumb owned the domain name www.woosterfloral.com. Wooster Floral & Gifts, a competing flower shop, brought this lawsuit under the Deceptive Trade Practices Act seeking to block Green Thumb from using the address. The trial court ruled in favor of Green Thumb, finding that Green Thumb's use of the domain name was unlikely to cause confusion as to the source of goods or services because the home page was clearly identified as "Green Thumb Floral" and there was no use of the trade name "Wooster Floral" within the website. The court of appeals affirmed. The Supreme Court affirmed, holding that, under both federal precedent and the plain terms of the Ohio statute, a consumer landing on Green Thumb's website was unlikely to be confused about the entity that would be fulfilling the consumer's order.